INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ORIC Pharmaceuticals, Inc.- ORIC

Pomerantz LLP is investigating potential securities fraud claims against ORIC Pharmaceuticals following a 41% stock price decline on March 31, 2026. The drop occurred after the company announced that its prostate cancer treatment (rinzimetostat/ORIC-944) performed roughly as effectively as competitors, falling short of expectations that it would be the best-in-class PRC2 blocker.

05/12/2026, 5:41 PM • GlobeNewswire

ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

ORIC Pharmaceuticals announced equity inducement grants of 80,000 non-qualified stock options and 15,000 restricted stock units to a new non-executive employee hired in March 2026. The grants were approved by the Compensation Committee under Nasdaq Rule 5635(c)(4) and vest over time based on continued employment.

04/03/2026, 4:30 PM • GlobeNewswire

ORIC Pharmaceuticals Stock Nosedives 25% After Hours: What Is Going On?

ORIC Pharmaceuticals (NASDAQ: ORIC) surged 3.94% during regular trading but plummeted 24.86% in after-hours trading despite releasing positive Phase 1b clinical data for its lead drug candidate rinzimetostat in combination with darolutamide for metastatic castration-resistant prostate cancer. The treatment showed an 84% radiographic progression-free survival rate with favorable safety outcomes, and the company selected a 400 mg once-daily dose for Phase 3 trials expected to begin in H1 2026. The sharp after-hours decline suggests investor caution around early-stage results or profit-taking.

04/01/2026, 2:48 AM • Benzinga

Precision Killers: Why Big Pharma is Betting Billions to Beat a $170B Patent Cliff

The precision oncology market is projected to grow from $110 billion to $225.65 billion by 2032, driven by Big Pharma's race to acquire registration-ready assets ahead of a $170 billion patent cliff through 2030. Several biotech companies are advancing promising clinical programs: Oncolytics Biotech strengthened its leadership team for pelareorep development in gastrointestinal cancers; Nurix is executing pivotal studies for its BTK degrader bexobrutideg in chronic lymphocytic leukemia; Erasca reported early clinical data for its pan-RAS molecular glue ERAS-0015; Foghorn raised $50 million for its SMARCA4-targeting program; and ORIC presented strong Phase 1b data for rinzimetostat in prostate cancer.

01/14/2026, 10:52 AM • Benzinga

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, demonstrating strong systemic and CNS activity in NSCLC patients with EGFR exon 20 mutations, with high objective response rates and a competitive safety profile.

12/05/2025, 8:00 PM • GlobeNewswire

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025

ORIC Pharmaceuticals presented promising Phase 1b trial results for enozertinib, a potential treatment for non-small cell lung cancer (NSCLC) with EGFR mutations, showing strong systemic and CNS activity with favorable safety profile.

12/04/2025, 9:45 PM • GlobeNewswire

ORIC® Pharmaceuticals Announces Publication in Cancer Research on the Discovery and Development of Enozertinib, a Highly Selective, Brain-Penetrant EGFR Inhibitor

ORIC Pharmaceuticals published research in Cancer Research detailing enozertinib, a highly selective brain-penetrant EGFR inhibitor targeting non-small cell lung cancer mutations, demonstrating potential for treating intracranial disease.

11/06/2025, 4:00 PM • GlobeNewswire